Inspire Investing LLC Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Inspire Investing LLC increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 13.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,242 shares of the biopharmaceutical company’s stock after purchasing an additional 4,148 shares during the quarter. Inspire Investing LLC’s holdings in Amicus Therapeutics were worth $350,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in Amicus Therapeutics during the 2nd quarter worth about $89,000. Sage Capital Advisors llc purchased a new stake in Amicus Therapeutics during the 2nd quarter worth about $103,000. Old Well Partners LLC purchased a new stake in Amicus Therapeutics during the 4th quarter worth about $180,000. EntryPoint Capital LLC increased its position in Amicus Therapeutics by 278.8% during the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 9,729 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in Amicus Therapeutics during the 1st quarter worth about $225,000.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $11.22 on Tuesday. The firm has a market capitalization of $3.32 billion, a P/E ratio of -22.90 and a beta of 0.69. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. The business’s 50-day simple moving average is $11.05 and its 200-day simple moving average is $10.69.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. Amicus Therapeutics’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.15) EPS. Equities analysts predict that Amicus Therapeutics, Inc. will post -0.08 EPS for the current year.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 6,100 shares of the business’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Bradley L. Campbell sold 6,100 shares of the business’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,382,718.34. The disclosure for this sale can be found here. Insiders have sold a total of 21,100 shares of company stock valued at $226,375 in the last three months. Corporate insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on FOLD. Wells Fargo & Company began coverage on Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price objective for the company. Jefferies Financial Group began coverage on Amicus Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $18.00 price target for the company. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. JPMorgan Chase & Co. lowered their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a report on Friday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.00.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.